Page last updated: 2024-09-05

erlotinib hydrochloride and Nasopharyngeal Neoplasms

erlotinib hydrochloride has been researched along with Nasopharyngeal Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Fan, Q; Zhang, F; Zhang, J; Zhang, Y; Zhou, F; Zou, Q	1
Chen, JP; Hsu, YB; Lan, MC; Lan, MY; Lu, YJ	1
Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B	1

Trials

1 trial(s) available for erlotinib hydrochloride and Nasopharyngeal Neoplasms

Article	Year
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. American journal of clinical oncology, 2012, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate	2012

Article

Year

A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.

American journal of clinical oncology, 2012, Volume: 35, Issue:3

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate

2012

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Nasopharyngeal Neoplasms

Article	Year
Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells. Annals of palliative medicine, 2020, Volume: 9, Issue:5 Topics: Chemoradiotherapy; DNA Damage; Erlotinib Hydrochloride; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms	2020
Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells. International journal of nanomedicine, 2020, Volume: 15 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Graphite; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Polyethylene Glycols	2020

Article

Year

Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells.

Annals of palliative medicine, 2020, Volume: 9, Issue:5

Topics: Chemoradiotherapy; DNA Damage; Erlotinib Hydrochloride; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms

2020

Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells.

International journal of nanomedicine, 2020, Volume: 15

Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Graphite; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Polyethylene Glycols

2020